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Abstract 
Depression is one the common psychiatric disorders through the world. Nitric 
oxide (NO) and N-methyl-D-aspartate receptor (NMDA-R) are involved in the 
pathophysiology of depression. Previous studies have been reported various 
pharmacological properties for ellagic acid (EA). We aimed to evaluate possible 
involvement of NMDA-NO pathway in the antidepressant-like effect of EA. To 
do this, we used relevant behavioral tests to evaluate depressive-like behavior. 
In order to find effective and sub-effective doses of agents, mice treated with 
EA (6.25, 12.5, 25, 50 and 100 mg/kg), L-NAME (5 and 10 mg/kg), L-arg (25 
and 50 mg/kg), NMDA (75 and 150 mg/kg) and ketamine (0.25 and 0.5 mg/kg). 
Furthermore, mice were treated with combination of sub-effective dose of EA 
plus sub-effective doses of L-NAME and/or ketamine as well as treated with 
effective dose of EA in combination of effective doses of L-arg and/or NMDA. 
Level of NO and gene expression of NR2A and NR2B subunits of NMDA-R 
were assessed in the hippocampus. Results showed that EA dose dependently 
provoked antidepressant-like effects and also decreased the hippocampal NO 
level as well as expression of NMDA-Rs. Co-administration of sub-effective 
doses of L-NAME or ketamine with sub-effective dose of EA potentiated the 
effect of EA on behaviors, NO level as well as NMDA-Rs gene expression in 
the hippocampus. However, co-treatment of effective dose of EA with effective 
doses of L-arg or NMDA mitigated effects of EA.  In conclusion, our data 
suggested that NMDA-NO, partially at least, are involved in the antidepressant-
like effect of EA. 
Keywords: Ellagic acid; NMDA-NO pathway; antidepressant-like effect; mice 
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Abbreviations 
EA: ellagic acid, NO: nitric oxide, NMDA-R: N-methyl-D-aspartate receptor, 
NOS: nitric oxide synthase, L-arg: L-arginine, L-NAME: NG-L-arginine methyl 
ester, OFT: open field test, FST: forced swimming test. 
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Introduction 
Currently, depression is recognized as one of the most common psychiatric 
disorders throughout the world (Ghanean, Ceniti et al. 2018). Depression now 
has become a community health concern, because is associated with high 
morbidity and mortality; it brings a lot of economic burden to society (Silva, 
Galvao et al. 2014, McIntyre, Ng-Mak et al. 2017). Commonly prescribed 
antidepressants which are mostly regulating monoaminergic transmission exert 
few desired outcomes and many patients don’t have complete response to these 
drugs (Arroll, Macgillivray et al. 2005, Berton and Nestler 2006). Considering 
the fact of increasing prevalence of depression (Compton, Conway et al. 2006), 
there is a pressing need to introduce new effective agents with promising 
pharmacological possessions and low side effects. 
In this regard, several studies have been determined that glutamate, an 
excitatory amino acid, plays a potential role in the pathophysiology of mood 
disorders such as depression (Sanacora, Zarate et al. 2008, Ostadhadi, Ahangari 
et al. 2016). It has been shown that increase in the hippocampal glutamatergic 
activity via NMDA receptors change the hippocampus plasticity and 
participates in the pathophysiology of depression (Amiri, Alijanpour et al. 
2016). Clinical evaluations revealed that the treatment with NMDA receptor 
antagonists such as ketamine mitigated the depressive symptoms in patients 
(Zarate, Singh et al. 2006). Also, preclinical studies showed that acute 
administration of NMDA antagonists produces antidepressant-like effects in 
rodents (Autry, Adachi et al. 2011, Ostadhadi, Khan et al. 2016, Lee, Ko et al. 
2018). Evidences demonstrated that NMDA receptors are involved in the 
mechanism of action of certain antidepressant drugs (Szasz, Mike et al. 2007).     
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It has been well-determined that activation of NMDA receptors stimulates NO 
production in the brain. NO, synthesized from L-arginine by NOS, is a mediator 
in the CNS and it is involved in neurotransmission and synaptic plasticity 
(Esplugues 2002). It has been determined that NO is involved in regulation of 
several (patho) physiologic behavioral and emotional functions (Zhu, Dong et 
al. 2017, Inserra, Mastronardi et al. 2018, Matsumoto, Matsumoto et al. 2018).  
NO/cGMP signaling pathway has been known as an interesting target for mood 
disorders (yan Zhou, Zhang et al. 2017, Walia, Garg et al. 2018). Previous 
studies have demonstrated that NOS inhibitors possessed antidepressant-like 
effects in rodents as well as mediated antidepressant-like properties of effective 
agents (Tomaz, Cordeiro et al. 2014, Khan, Ostadhadi et al. 2016). In this 
regards, previous studies showed that inhibition of NMDA-NO pathway is 
involved in the antidepressant-like effects of some related agents (Contestabile 
2000, Khan, Ostadhadi et al. 2016, Araújo, de Melo et al. 2018). 
2,3,7,8 tetrahydroxybenzo pyrano [5, 4, 3-cde] benzopyran-5-10-dione, a 
polyphenolic metabolite, known as EA is present either in free form or as part 
of more complex molecules (ellagitannins). EA is found in many plants such as 
cranberries, pecans, pomegranate, grapes, raspberries seed, blackberries, 
strawberries and nuts (Ríos, Giner et al. 2018). Previous studies have been 
reported several pharmacological properties for EA including anti-bacterial, 
anti-inflammatory, immunoregulatory and anti-tumor effects (Chao, Hsu et al. 
2009, García-Niño and Zazueta 2015, Ríos, Giner et al. 2018). It has been 
demonstrated that EA via attenuation of nitric oxide level exerts neuroprotective 
effect in the brain and sciatic nerve in streptozotocin-induced diabetic rats 
(Uzar, Alp et al. 2012). It has been suggested that EA exhibits neuro-protective 
effect and protects the brain from oxidative and inflammatory challenges (Uzar, 
Alp et al. 2012, Farbood, Sarkaki et al. 2015). Preclinical examinations 
determined antidepressant-like effects for EA (Dhingra and Chhillar 2012, 
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Girish, Raj et al. 2012),  however, its mechanism of action has not yet been 
clearly specified and further studies are warranted to determine the mechanism 
of the antidepressant-like action of EA. 
Considering the above-mentioned studies which suggested 1) a critical role for 
the NMDA-R/NO pathway in the pathogenesis of mood disorders such as 
depression and also 2) neuroprotective effect for EA, in the current study we 
aimed to evaluate the involvement of the NMDA-R/NO pathway in the 
antidepressant-like effect of EA in male mice. 
Considering the above-mentioned studies which suggested a critical role for the 
NMDA-NO pathway in the pathogenesis of the depression and also with regard 
to the neuro-protective effects mentioned for the EA, the current study aimed to 
evaluate the involvement of the NMDA-NO pathway in the antidepressant-like 
effect of EA in male mice. 
Material and methods 
Animal  
Three hundred and twelve male NMRI mice weighing 25-30 g were obtained 
from the Pasteur Institute, Tehran, Iran. Mice were kept at standard laboratory 
conditions including temperature of 21-23 ⁰C, 12h regular light/dark cycle and 
free access to food and water. All tests were done between 10:00 and 14:00 h. 
All stages of experimentation were carried out in accordance with the 
regulations of the University and the Guide for the Care and Use of Laboratory 
Animals of National Institutes of Health (Ethics code: 
IR.SKUMS.REC.1397.18) and Guide for the Care and Use of Laboratory 
Animals (8th edition, National Academies Press). Full efforts were made to 
diminish the use of animals and to improve their wellbeing. Animal randomly 
divided into the experimental groups (n=8 in each group). In order to prevent 
the effects of manipulation by different experimenters on animals and to 
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IP
T
minimize manipulations, all experiments were conducted by a single 
experimenter. Each experimental group was contained 8 mice for behavioral 
tests and 4 samples for molecular assessments (gene expression and NO level). 
Treatments 
The following agents were used in this study: 1) EA. 2) L-NAME, a non-
selective nitric oxide synthase or NOS inhibitor. 3) L-arg, a NO precursor. 4) 
NMDA, a selective agonist of the NMDA receptors. 5) Ketamine, a non-
selective antagonist of the NMDA receptors.  All drugs were bought from the 
Sigma, St Louis, MO, USA. All drugs were dissolved in physiological saline 
contained 5% DMSO (Haj-Mirzaian, Amini-Khoei et al. 2017) which 
considered as vehicle. All drugs were administrated via intraperitoneal (i.p.) 
rout with a volume of 5ml/kg body weight. We treated mice with L-arg 
(30min), L-NAME (45 min), NMDA (15 min), ketamine (60 min) and EA (60 
min) prior to tests. The dose and time of drug injections were chosen according 
to previous studies (Girish, Raj et al. 2012, Amiri, Alijanpour et al. 2016, Amiri, 
Haj-Mirzaian et al. 2016, Bedel, Kencebay Manas et al. 2017, Haj-Mirzaian, 
Amiri et al. 2018), as well as our pilot studies. Each mouse was used only for 
one test (same mice were used for the FST and the OFT and different set of 
mice were used for the splash test).  
 
Study design 
In the current study we performed valid behavioral tests are relevant to 
depression including open field test (OFT), forced swimming test (FST) and 
splash test. Our study was consisted of 5 steps (Fig 1) as follows: 
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Fig 1. Schematic of the study design 
Experiment 1: dose-effect study of EA 
 Examined the effects of different doses of the EA (6.25, 12.5, 25, 50 and 100 
mg/kg, 60 min prior to tests) on the behavioral tests. The goal of this step was to 
find the effective and sub-effective doses of the EA.  
Experiment 2: dose-effect study of NOS inhibitor/activator 
 Evaluated the effects of L-NAME (5 and 10 mg/kg, 45 min prior to tests) and 
L-arg (25 and 50 mg/kg, 30 min before tests) on depressive-like behaviors. In 
this step we aimed to find effective and sub-effective doses of the L-NAME and 
L-arg. 
Experiment 3: dose-effect study of NMDA agonist/antagonist 
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 We evaluated the effects of the NMDA (75 and 150 mg/kg, 15 min prior to 
tests) and the ketamine (0.25 an 0.5 mg/kg, 60 min before tests) on depressive-
like behaviors. In this experiment we expected to find effective and sub-
effective doses of the NMDA and ketamine.  
Experiment 4: evaluation of possible involvement of NO in the effect of EA 
We examined the effect of co-treatment of effective dose of the EA (25 mg/kg) 
with effective dose of the L-arg (50 mg/kg) on depressive-like behaviors. We 
also evaluated the effect of co-administration of sub-effective dose of EA (6.25 
mg/kg) with sub-effective dose of L-NAME (5 mg/kg). Animals in this trial 
received L-arg 30 min prior to test and 30 min after EA as treated with L-
NAME 45 min prior to test and 15 min after EA (Fig 2). 
 
Fig 2. Schematic of the experiment 4 
Experiment 5: evaluation of possible involvement of NMDA in the effect of 
EA 
 The effect of co-treatment of effective dose of the EA (25 mg/kg) with 
effective dose of the NMDA (150 mg/kg) on depressive-like behaviors was 
evaluated. Moreover, the effect of co-administration of sub-effective dose of EA 
(6.25 mg/kg) with sub-effective dose of ketamine (0.25 mg/kg) was assessed.  
Animals in this trial received NMDA 15 min prior to test and 45 min after EA 
as treated with ketamine and EA as simultaneously (60 min before test) (Fig 3). 
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Fig 3. Schematic of the experiment 5 
Behavioral tests 
Forced swimming test (FST) 
FST was performed as a valid test for measuring despair behavior in mice 
which observes as increased in the immobility time (Porsolt, Bertin et al. 1977, 
Lu, Ross et al. 2008) . In this test, mice were individually located in an open 
glass cylinder (diameter: 10 cm, height: 25 cm) occupied with 19 cm water (23 
± 1 °C). Animals were allowed to swim for duration of 6 min and the 
immobility time was recorded in the latter 4 min by an experimenter blinded to 
the treatments. Motionless time was considered when the mouse continued 
immobile in the water and did only those essential movements to keep its head 
above the water. 
Open field test (OFT) 
The OFT was performed to evaluate the locomotion following treatments 
(Amiri, Alijanpour et al. 2016). The OFT was done immediately before the FST 
to consider ambulatory behavior as well as to confirm that adjustments which 
occur in motor activity did not affect the immobility time in the FST(Rodrigues, 
Rocha et al. 1996) . The OFT device was made of white opaque Plexiglas 
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(50  cm  ×  50  cm  ×  30  cm), which was softly illumined. Each mouse 
was mildly situated on the center square (30  cm  ×  30  cm), and 
presentations were recorded by a camera for 5  min. The apparatus was cleaned 
with 70% ethanol after experiment of each mouse. The distance moved 
(horizontal activity, number of crossing by 4 foots from each square) and the 
number of rearings (vertical activity) was recorded. 
Splash test 
We performed the splash test to evaluate the self-care behavior. In this test 
grooming activity time designated an indirect ration for palatable solution 
drinking. To do this, a 10% sucrose solution was scattered on the dorsal coat of 
mice while they were in their home cages and mice were recorded for 5  min. 
Grooming movements were including nose/face cleaning, head washing, and 
body grooming which were recorded by a person blinded to treatments 
(Ducottet and Belzung 2004) . 
Nitrite assay 
Nitrite level was measured in the hippocampus samples based on method 
described in previous studies (Kordjazy, Haj-Mirzaian et al. 2015, Haj-
Mirzaian, Amiri et al. 2018). In brief, mice were sacrificed under anesthesia 
using diethyl ether, and hippocampus was dissected on the ice-cold surface and 
directly place into liquid nitrogen. Hippocampus homogenates were prepared, 
and nitrite concentrations were measured using colorimetric assay based on the 
Griess reaction. Briefly, each well was loaded with 100  μL samples and mixed 
with 100  μL Griess reagent. The absorbance was measured at 540  nm in an 
automated plate reader, after ten minutes incubation at room temperature. The 
level of Nitrite was determined by reference to a standard curve of sodium 
nitrite (Sigma, USA) and normalized to the weight of each sample. 
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Real-time RT-PCR analysis for assessment of the NR2A and NR2B NMDA 
receptors genes expression 
TRIzol reagent (Invitrogen) was used to extract total RNA from the 
hippocampi. After the reverse transcription of 1 μg of RNA using PrimeScript 
RT reagent kit (Takara Bio, Inc., Otsu, Japan), qRT-PCR was done to determine 
alterations in the mRNA levels of favorite genes. qRT-PCR was done on a light 
cycler device (Roche Diagnostics, Mannheim, Germany) using SYBR Premix 
Ex Taq technology (Takara Bio). Thermal cycling conditions were including an 
initial activation step for 30 s at 95 °C afterwards 45 cycles as well as a 
denaturation step for 5 s at 95 °C and a combined annealing/extension step for 
20 s at 60 °C. Melting curve analysis was done to confirm whether all primers 
generated a single PCR product. The genes and their primers are listed in Table 
1. Histone H2A variant, H2afz, was used as normalizer gene and variations in 
expression of each mRNA in comparison with H2afz was measured based on 2
−
 
ΔΔCt 
relative expression formula, as described previously (Murgatroyd, Peña et 
al. 2015, Amiri, Haj-Mirzaian et al. 2017). 
Table 1: primer sequences 
name sequence 
Nr2a-F CTCAGCATTGTCACCTTGGA 
Nr2a-R GCAGCACTTCTTCACATTCAT 
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Nr2b-F CTACTGCTGGCTGCTGGTGA 
Nr2b-R GACTGGAGAATGGAGACGGCTA 
H2afz-F TCATCGACACCTGAAATCTAGGA 
H2afz-R AGGGGTGATACGCTTTACCTTTA 
 
Statistics 
Comparison between the groups was analyzed using one-way and two-way 
analyses of variance (ANOVAs), followed by tukey's multiple comparison test. 
GraphPad Prism software (version 7) was used for data analysis. P  <  0.05 
was considered statistically significant. 
Results 
Effect of EA on the depressive-like behaviors  
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One-way ANOVA revealed that there are significant difference among 
experimental groups in the FST (F (5, 42) = 19.03, P<0.001), splash test (F (5, 
42) = 25.47, P<0.001), horizontal activity in the OFT (F (5, 42) = 2.343, 
P<0.05). However there is no significant difference among groups in the 
vertical activity of the OFT (F (5, 42) = 1.388, P>0.05). Tukey's  post analysis 
showed that administration of EA at doses of 25 (P<0.05), 50 (P<0.001) and 
100 mg/kg (P<0.001) significantly decreased the immobility time in the FST n 
the splash test our data exposed that EA at doses of 12.5 (P<0.05), 25 (P<0.01), 
50 (P<0.001) and 100 mg/kg (P<0.001) significantly increased the grooming 
activity time in comparison with vehicle-treated group. Our findings 
demonstrated that administration of EA at dose of 100 mg/kg significantly 
reduced the horizontal activity when compared with vehicle-received mice 
(P<0.05) (Fig 4). 
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Fig. 4. Effect of administration of the EA at different doses on depressive -like 
behaviors in adult male mice, FST (A), splash test (B), horizontal activity in the 
OFT (C) and number of rearings in the OFT (D). Values are presented as the 
mean ± S.E.M from 8 animals and were analyzed one-way ANOVA. *P<0.05, 
**P<0.01 and ***P<0.001 compared with the vehicle-treated mice. 
Effects of inhibitor and precursor of NOS on the depressive-like behaviors 
One-way ANOVA revealed that there are significant difference among 
experimental groups in the FST (F (4, 35) = 12.04, P<0.001), splash test (F (4, 
35) = 41.11, P<0.001), horizontal activity in the OFT (F (4, 35) = 0.6861, 
P>0.05). However there is no significant difference among groups in the 
vertical activity of the OFT (F (4, 35) = 1.542, P>0.05) (Fig 5). Post- test 
analysis revealed that administration of L-NAME at dose of 10 mg/kg 
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significantly reduced the immobility time in the FST (P<0.05) in compared with 
the vehicle-treated mice. In addition administration of the L-arg at dose of 50 
mg/kg significantly increased the immobility time in the FST (P<0.05). 
 
Fig. 5. Effect of administration of the NOS inhibitor (L-NAME) and NO 
precursor (L-arg) at different doses on depressive -like behaviors in adult male 
mice, FST (A), splash test (B), horizontal activity in the OFT (C) and number of 
rearings in the OFT (D). Values are presented as the mean ± S.E.M from 8 
animals and were analyzed one-way ANOVA. *P<0.05 and **P<0.01 compared 
with the vehicle-treated mice. 
Effects of agonist and antagonists of NMDA-R on the depressant-like 
behaviors 
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One-way ANOVA revealed that there are significant difference among 
experimental groups in the FST (F (4, 35) = 74.10, P<0.001), splash test (F (4, 
35) = 21.00, P<0.001), vertical activity in the OFT (F (4, 35) = 4.290, P<0.05). 
However there is no significant difference among groups in the horizontal 
activity of the OFT (F (4, 35) = 1.383, P>0.05) (Fig 6). Results determined that 
NMDA agonist (150 mg/kg) significantly increased the immobility time in the 
FST in comparison with control counterpart (P<0.01). Furthermore, 
administration of ketamine at doses of 0.2 mg/kg (P<0.01) and 0.5 mg/kg 
(P<0.001) significantly decreased the immobility time in the FST in comparison 
with vehicle-received group. In case of splash test, we found that NMDA 
agonist (150 mg/kg) significantly reduced the grooming activity time (P<0.01) 
and ketamine at dose of 0.5 mg/kg significantly increased the grooming activity 
time in compared with vehicle -treated counterpart. In addition we observed that 
ketamine at dose of 0.5 mg/kg reduced the number of rearings (vertical activity) 
in compared with the vehicle group (P<0.05). 
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Fig. 6. Effect of administration of the NMDA agonist (NMDA) and NMDA 
antagonist (ketamine) at different doses on depressive -like behaviors in adult 
male mice, FST (A), splash test (B), horizontal activity in the OFT (C) and 
number of rearings in the OFT (D). Values are presented as the mean ± S.E.M 
from 8 animals and were analyzed one-way ANOVA. *P<0.05, *P<0.01 and 
***P<0.001 compared with the vehicle -treated mice. 
Involvement of NO in the antidepressant-like effects of EA 
Two-way ANOVA revealed that there are significant difference among 
experimental groups in the FST (F (6, 42) = 11.88, P<0.001) and the splash test 
(F (6, 42) = 33.37, P<0.001) (Fig 7). However there is no significant difference 
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among groups in the horizontal activity of the OFT (F (6, 42) = 3.49, P>0.05) 
and vertical activity in the OFT (F (6, 42) = 2.415, P>0.05).  
Post- test analysis determined that co-administration of sub-effective dose of L-
NAME (5 mg/kg) with sub-effective dose of EA (6.25 mg/kg) significantly 
decreased the immobility time in the FST (P<0.01). In this regard, co-
administration of effective dose of EA (25 mg/kg) with L-arg (50 mg/kg) 
significantly increased the immobility time in the FST (P<0.05) when compared 
with the vehicle -treated counterpart. Furthermore, co-applied of the L-NAME 
with sub-effective dose of EA decreased the immobility time in compared with 
the group received EA at dose of 6.25 mg/kg (P<0.05). Co-administration of the 
L-arg with EA at dose of 25 mg/kg significantly increased the immobility time 
in compared with the group received EA at dose of 25 mg/kg (P<0.01).  
 In the splash test we observed that co-treatment of sub-effective dose of L-
NAME (5 mg/kg) with sub-effective dose of EA (6.25 mg/kg) significantly 
increased the grooming activity time (P<0.01). As, co-administration of 
effective dose of EA (25 mg/kg) with L-arg (50 mg/kg) significantly decreased 
the grooming activity (P<0.001) when compared with the vehicle -treated 
counterpart. Co-applied of the L-NAME with sub-effective dose of EA 
increased the grooming activity time in compared with the group received EA at 
dose of 6.25 mg/kg (P<0.05). Co-administration of the L-arg with EA at dose of 
25 mg/kg significantly decreased the grooming activity time in compared with 
the group received EA at dose of 25 mg/kg (P<0.001).  
In addition we did not find significant differences amongst groups either in 
horizontal or vertical activities in the OFT. 
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Fig. 7. Involvement of NO in antidepressant effects of EA on the immobility 
time in the FST (A), grooming activity in the splash test (B) and the horizontal 
activity (C) and vertical activity (D) in the OFT in adult male mice. Values are 
expressed as the mean ± S.E.M from 6 to 8 animals and were analyzed using 
two-way ANOVA followed by Tukey’s post hoc test. *P<0.05, **P<0.01 and 
***P<0.001 compared with the vehicle -treated counterpart, $P<0.05 compared 
with group received EA at dose of 6.25 mg/kg, ##P<0.01 and ###P<0.001 
compared with mice treated with EA at dose of 25 mg/kg. 
Involvement of NMDA in the antidepressant-like effects of EA 
Two-way ANOVA revealed that there are significant difference among 
experimental groups in the FST (F (6, 42) = 40.63, P<0.001) and the splash test 
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(F (6, 42) = 35.61, P<0.001). However there is no significant difference among 
groups in the horizontal activity of the OFT (F (6, 42) = 2.533, P>0.05) and 
vertical activity in the OFT (F (6, 42) = 2.195, P>0.05) (Fig 8).  
Post- test analysis determined that co-administration of sub-effective dose of 
ketamine (0.25 mg/kg) with sub-effective dose of EA (6.25 mg/kg) significantly 
decreased the immobility time in the FST (P<0.001). Furthermore, co-
administration of effective dose of EA (25 mg/kg) with NMDA (150 mg/kg) 
significantly increased the immobility time in the FST (P<0.05) when compared 
with the vehicle -treated counterpart. Co-applied of the ketamine with sub-
effective dose of EA decreased the immobility time in compared with the group 
received EA at dose of 6.25 mg/kg (P<0.05). Co-administration of the  NMDA 
with EA at dose of 25 mg/kg significantly increased the immobility time in 
compared with the group received EA at dose of 25 mg/kg (P<0.01). 
In the splash test we observed that co-treatment of sub-effective dose of 
ketamine (0.25 mg/kg) with sub-effective dose of EA (6.25 mg/kg) significantly 
increased the grooming activity time (P<0.001). In addition, co-administration 
of effective dose of EA (25 mg/kg) with NMDA (150 mg/kg) significantly 
decreased the grooming activity (P<0.001) when compared with the vehicle -
treated counterpart. Co-applied of the ketamine with sub-effective dose of EA 
increased the grooming activity time in compared with the group received EA at 
dose of 6.25 mg/kg (P<0.01). Co-administration of the NMDA with EA at dose 
of 25 mg/kg significantly decreased the grooming activity time in compared 
with the group received EA at dose of 25 mg/kg (P<0.01).  
In addition we did not find significant differences amongst groups either in 
horizontal or vertical activities in the OFT. 
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Fig. 8. Involvement of NMDA in anti-depressant- like effects of EA on the 
immobility time in the FST (A), grooming activity in the splash test (B) and the 
horizontal activity (C) and vertical activity (D) in the OFT in adult male mice. 
Values are expressed as the mean ± S.E.M from 8 animals and were analyzed 
using two-way ANOVA followed by Tukey’s post hoc test. *P<0.05, and 
***P<0.001 compared with the vehicle- treated counterpart, $P<0.05 and 
$$P<0.05 compared with group received EA at dose of 6.25 mg/kg, ##P<0.01 
compared with mice treated with EA at dose of 25 mg/kg. 
EA decreased the level of nitric oxide in the hippocampus 
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Two-way ANOVA exposed that there are significant difference among 
experimental groups in case of NO concentration in the hippocampus (F (4, 20) 
= 17.42, P<0.001) (Fig 9). Post- test analysis showed that administration of EA 
at dose of 25 mg/kg significantly reduced the level of NO in the hippocampus in 
compared with the vehicle -received group (p<0.01). Furthermore, we observed 
that co-administration of EA at effective dose of 25 mg/kg with L-arg (50 
mg/kg) significantly increased the level of NO in the hippocampus when 
compared with the group received EA at dose of 25 mg/kg (P<0.05). We 
showed that co-administration of sub-effective dose of EA (6.25 mg/kg) with 
sub-effective dose of L-NAME (5 mg/kg) significantly decreased the NO level 
in the hippocampus in compared with the vehicle group (P<0.01) and the group 
received EA at dose of 6.25 mg/kg (P<0.05).  
 
 
Fig. 9. Effect of EA and NOS inhibitor as well as NO precursor on the NO level 
in the hippocampus.  Values are expressed as the mean ± S.E.M from 4 animals 
and were analyzed using two-way ANOVA followed by Tukey’s post hoc test. 
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**P<0.05 compared with the vehicle -treated counterpart, # P<0.05 compared 
with the group received EA at dose of 25 mg/kg and $P<0.05 compared with 
the group received EA at dose of 6.25 mg/kg.  
EA modulates the expression of NR2A and NR2B subunits of the NMDA-R 
in the hippocampus 
Two- way ANOVA analysis showed that there are significant differences 
among experimental groups in case of expression of NR2A (F (4, 12) = 5.143, P 
< 0.01) and NR2B (F (4, 12) = 4.696, P < 0.05) in the hippocampus (Fig. 10). 
Post- test analysis showed that EA at dose of 25 mg/kg significantly decreased 
the expression of NR2A subunit of the NMDA-R in comparison with the 
control group (P<0.05). Also, we determined that administration of the EA at 
dose of 6.25 mg/kg significantly increased the expression of the NR2B receptor 
in compared with the control group (P<0.05). Furthermore, co-administration of 
the ketamine (sub-effective dose of 0.25) with sub-effective dose of EA (6.25 
mg/kg) significantly decreased the expression of the NR2B receptor in 
compared with the group- received EA at dose of 6.25 mg/kg.  
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Fig 10. The expression of NR2A and NR2B subunits of the NMDA-R in the 
hippocampus. Values are expressed as the mean ± S.E.M from 4 samples and 
were analyzed using two-way ANOVA followed by Tukey’s post hoc test. 
*P<0.05 compared with the normal group and 
#
P<0.05 compared with the group 
received EA at dose of 6.25 mg/kg. 
Discussion 
Results of the present study showed that EA in a dose dependent manner 
exerted antidepressant-like effects in the valid behavioral tests related to 
depression including FST, splash test. We observed that administration of L-
NAME similar to ketamine produced antidepressant-like effects while treatment 
with L-arg such as NMDA caused a depressive-like behavior in mice. In order 
to determine the possible mechanisms of action of the EA, EA in combination 
with L-NAME, L-arg, ketamine and NMDA was administered. Findings 
determined that at least in part, NMDA-NO pathways mediated the 
antidepressant-like effect of EA in mice.  
FST is a valid screening test for the evaluation of new antidepressants. In 
the FST, the increase in immobility time of rodents indicating depressive-like 
behavior (Cryan and Holmes 2005, Haj-Mirzaian, Amini-Khoei et al. 2017). In 
this test increase in immobility time reflects the inability of mice to deal with an 
acute unescapable challenge expressing the depressive-like behaviors. The 
splash test is a recognized valid test assessing the self-care difficulties and 
motivation in rodents. In the splash test a poor response to sucrose 10% as 
decrease in the grooming time representing a disorder in motivation and self-
care behaviors (Amini-Khoei, Mohammadi-Asl et al. 2017). The decrease in the 
grooming activity time reflects depressive-like behavior. In addition, we 
performed the OFT to confirm that locomotor activity of mice following 
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treatments does not affect the FST results, and the immobility of animals in the 
FST is not allied with their hypo-locomotion (Haj-Mirzaian, Amiri et al. 2018). 
In the other word, OFT was conducted immediately before the FST to assess 
ambulatory behavior of mice and approve that disparities which happen in 
motor activity did not affect the duration of immobility in the FST. 
EA, a chromene-dione derivative (2,3,7,8-tetrahydroxy-chromeno[5,4,3-
cde]chromene-5,10-dione; C14H6O8, is a common metabolite in some plants, 
several fruits (pomegranates, persimmons, raspberries, black raspberries, wild 
strawberries, peaches, plums) and seeds (walnuts, almonds), and vegetables 
(Ríos, Giner et al. 2018). Previous studies have been suggested several 
pharmacological effects for EA including anti-inflammatory, neuroprotective, 
and antioxidant properties (Seeram, Adams et al. 2005, de Oliveira 2016). It has 
been proposed that EA can scavenge damaging radicals such as reactive oxygen 
species (ROS) and reactive nitrogen species (RNS) (Priyadarsini, Khopde et al. 
2002). In vitro studies reported that EA can dose dependently decrease the 
activation of inducible NOS (iNOS) in the stimulated macrophages and reduce 
the NO concentration in these cells (Kassim, Achoui et al. 2010). EA possessed 
neuro-protective effects in the brain against various damages. These defensive 
properties are resulted from positive effects on neuro-inflammatory responses 
and (pro) oxidant mediators such as NO, cytokines and superoxide radicals (de 
Oliveira 2016).    
Few studies have been conducted on the antidepressant-like effects of EA 
in animal models. In this context studies have been demonstrated that 
monoaminergic system, nitric oxide pathway and brain derived neurotrophic 
factor (BDNF) are involved in the antidepressant-like effect of EA in rodents 
(Dhingra and Chhillar 2012, Girish, Raj et al. 2012, Bedel, Kencebay Manas et 
al. 2017). However, the precise mechanisms underlying the antidepressant-like 
effect of EA are not yet fully specified. Findings of the current study 
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demonstrated that EA dose dependently exerts antidepressant-like effects in the 
FST and the splash test. We showed that EA at doses of 12.5, 25, 50 and 100 
mg/kg significantly decreases the immobility time in the FST as well as 
increased the grooming activity time in the splash test. However, EA at dose of 
6.25 mg/kg possesses any positive effects in the related behavioral tests and this 
dose considered as sub-effective dose. These results are in agreement with 
previous studies which have been reported that EA possessed antidepressant-
like effects in rodents (Dhingra and Chhillar 2012, Girish, Raj et al. 2012). In 
addition we found that EA, except at dose of 100 mg/kg has no effect on 
locomotor activity in the OFT.  
Ample evidence demonstrated that glutamatergic system has critical role in the 
pathophysiology of psychiatrics such as depression. In this regards, both clinical 
and preclinical studies have showed that NMDA receptor antagonists exerted 
antidepressant (-like) effects (Berman, Cappiello et al. 2000, Tokita, Yamaji et 
al. 2012, Zorumski and Izumi 2012). Previously, it has been well-known that 
acute administration of ketamine possesses antidepressant-like effects in 
behavioral tests relevant to depression including FST and splash test (Maeng, 
Zarate Jr et al. 2008, Brachman, McGowan et al. 2016). Clinical investigations 
have been reported that treatment with ketamine at sub-anesthetic dose lead to 
rapid, strong, and relatively constant antidepressant effects in patients with 
treatment-resistant depression(Maeng and Zarate 2007, Denk, Rewerts et al. 
2011, Rybakowski, Permoda‐Osip et al. 2013). Furthermore, experimental 
researches have been determined that NMDA agonists provoked depressive-like 
behaviors in relevant behavioral tests in rodents (Ostadhadi, Ahangari et al. 
2016, Ostadhadi, Norouzi-Javidan et al. 2017).  In this study using valid 
behavioral tasks related to depression in rodents, we showed that administration 
of ketamine decreases immobility time in the FST and increases grooming 
activity time in the splash test.  Moreover, treatment of mice with the NMDA 
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increased immobility time in the FST and decreased grooming activity time in 
the splash test. Our results are in line with abovementioned studies which have 
been clarified that NMDA receptor activation leads to depressive-like behavior 
in rodents.  Our findings present that ketamine blocks NMDA receptors that 
may account for its antidepressant-like effects in male mice. In completing this 
hypothesis, our results showed that NMDA (150 mg/kg) can reverse the 
antidepressant-like effect of effective dose of the EA (25 mg/kg) as well as 
ketamine (0.25 mg/kg) can potentiated the antidepressant-like effect of sub-
effective dose of the EA (6.25 mg/kg). Our results proposing that blockade of 
NMDA receptors potently, at least in part, contributes to antidepressant-like 
effects of the EA in male mice. Real time RT-PCR findings showed that 
administration of EA at dose of 25 mg/kg significantly decreases the of NR2A 
subunit of the NMDA-R. Administration of the EA at dose of 6.25 mg/kg 
significantly increased the expression of the NR2B receptor. Co-administration 
of the sub-effective dose of ketamine with sub-effective dose of EA (6.25 
mg/kg) significantly decreased the expression of the NR2B receptor in 
compared with the group- received EA at dose of 6.25 mg/kg. Previous studies 
showed that alterations in NR2A and NR2B subunits of the NMDA-R involved 
in the pathophysiology of depression (Feyissa, Chandran et al. 2009, Zhang, Xu 
et al. 2013). We showed that co-applied of the ketamine with sub-effective dose 
of EA potentiated the antidepressant-like effect of sub-effective dose of the EA 
as co-administration of the NMDA with effective dose of the EA mitigated the 
antidepressant-like effect of effective dose of the EA. Given that, our results 
provided evidence that NMDA receptor complex can be considered as a target 
for discovery of novel antidepressants. 
Nitric oxide as a neuromodulator has pivotal role in regulation of 
physiological functions in the CNS (Chong, Ai et al. 2018). Clinical studies 
have been determined that level of the NO significantly increases in the plasma 
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samples of MDD patients (Schiavone, Neri et al. 2016, Lu, Zhang et al. 2018). 
Previous studies have been demonstrated that NO can be considered as a 
biomarker for detection of depression. In this regards it has been shown that 
following treatment with antidepressant drugs the level of NO significantly 
reduced in response to treatment (Bersani, Wolkowitz et al. 2016, Loeb, Feve et 
al. 2017). Preclinical studies clarified that administration of NOS inhibitors led 
to antidepressant-like properties in behavioral tests related to depression in 
animals. In this regards literature said that inhibition of the NOS involves in the 
antidepressant-like effects of new agents with antidepressant-like properties 
(Ostadhadi, Ahangari et al. 2016, Ostadhadi, Khan et al. 2016). Findings of the 
current study showed that administration of the L-NAME exerts antidepressant-
like effects in the FST and the splash test manifested by decreasing in the 
immobility time and increasing in the grooming activity time, respectively. 
Furthermore, we observed that administration of the L-arg led to depressive-like 
behaviors in the FST and splash test. In addition we observed that EA 
significantly decreases the NO level in the hippocampus and in this concept L-
arg reversed and L-NAME potentiated the effect of sub-effective dose of EA on 
the hippocampal NO level. These results are in line with aforementioned 
previous studies which conformed that NOS inhibitors causes antidepressant-
like behavior and NO precursors provoked depressive-like actions. To support 
this, we evaluated the effect of combination therapy between EA and NO 
mediators. We showed that co-treatment of sub-effective dose of EA (6.25 
mg/kg) with sub-effective dose of L-NAME (5mg/kg) significantly leads to 
antidepressant-like behaviors in the FST and splash test. In addition, we 
observed that co-administration of effective dose of the EA (25 mg/kg) with l-
arg (50 mg/kg) significantly reverses the positive effect of the EA as shown by 
increasing in immobility time in the FST and decreasing in grooming activity 
time in the splash test. In our study, co-applied L-NAME with sub-effective 
dose of EA potentiated the antidepressant-like effect of the sub-effective dose of 
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the EA as co-administration of L-arg with effective dose of the EA significantly 
alleviated the antidepressant-like effect of the EA. Given that, our results 
suggest that attenuation of NO level potently, at least in part, contributes to 
antidepressant-like effects of the EA in male mice. Given that, our findings 
demonstrated that NMDA-NO pathway, partially at least involves in the 
antidepressant-like effect of EA in behavioral tests related to depression 
including FST and splash test.  
 
Conclusion  
In conclusion, findings of the present study provides evidence that, 1) EA dose 
dependently possesses antidepressant-like effects in behavioral tests related to 
depression, 2) NO is involved in the antidepressant-like effect of EA that way 
NOS inhibition potentiated the effect of sub-effective dose of EA and NO 
precursor mitigated the antidepressant-like effect of EA, 3) NMDA is involved 
in the antidepressant-like effect of EA that way ketamine potentiated the effect 
of sub-effective dose of EA and NMDA mitigated the antidepressant-like effect 
of EA. 
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Highlights 
Ellagic acid (EA) exerted antidepressant-like effect in mice 
Nitric oxide synthase inhibitor (L-NAME) possessed antidepressant-like effect 
NMDA receptor antagonist (ketamine) exerted antidepressant-like effect  
Sub-effective doses of the L-NAME and ketamine potentiated the 
antidepressant-like effect of sub-effective dose of EA 
Nitric oxide synthase inhibitor (L-arg) as well as NMDA receptor agonist 
reversed antidepressant-like effect of effective dose of EA 
EA decreased NO level as well as NR2A expression in the hippocampus 
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